Bayer/Algeta’s Xofigo Brings New Mechanism To Prostate Cancer Field
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA approved the first alpha particle-emitting radioactive therapeutic agent, Bayer/Algeta’s Xofigo (radium Ra 223 dichloride), for prostate cancer patients with symptomatic bone metastases, three months ahead of the expected PDUFA date.